Copyright Reports & Markets. All rights reserved.

Global Glioblastoma Multiforme Therapeutics Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Glioblastoma Multiforme Therapeutics Market Overview

      • 1.1 Product Overview and Scope of Glioblastoma Multiforme Therapeutics
      • 1.2 Glioblastoma Multiforme Therapeutics Segment by Type
        • 1.2.1 Global Glioblastoma Multiforme Therapeutics Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Temozolomide
        • 1.2.3 Bevacozumab
        • 1.2.4 Carmustine
      • 1.3 Glioblastoma Multiforme Therapeutics Segment by Application
        • 1.3.1 Glioblastoma Multiforme Therapeutics Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospitals
        • 1.3.3 Clinics
        • 1.3.4 Others
      • 1.4 Global Glioblastoma Multiforme Therapeutics Market by Region
        • 1.4.1 Global Glioblastoma Multiforme Therapeutics Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global Glioblastoma Multiforme Therapeutics Market Size
        • 1.5.1 Global Glioblastoma Multiforme Therapeutics Revenue (2014-2025)
        • 1.5.2 Global Glioblastoma Multiforme Therapeutics Production (2014-2025)

      2 Global Glioblastoma Multiforme Therapeutics Market Competition by Manufacturers

      • 2.1 Global Glioblastoma Multiforme Therapeutics Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Glioblastoma Multiforme Therapeutics Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Glioblastoma Multiforme Therapeutics Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Glioblastoma Multiforme Therapeutics Production Sites, Area Served, Product Types
      • 2.5 Glioblastoma Multiforme Therapeutics Market Competitive Situation and Trends
        • 2.5.1 Glioblastoma Multiforme Therapeutics Market Concentration Rate
        • 2.5.2 Glioblastoma Multiforme Therapeutics Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Glioblastoma Multiforme Therapeutics Production Market Share by Regions

      • 3.1 Global Glioblastoma Multiforme Therapeutics Production Market Share by Regions
      • 3.2 Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Glioblastoma Multiforme Therapeutics Production
        • 3.4.1 North America Glioblastoma Multiforme Therapeutics Production Growth Rate (2014-2019)
        • 3.4.2 North America Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Glioblastoma Multiforme Therapeutics Production
        • 3.5.1 Europe Glioblastoma Multiforme Therapeutics Production Growth Rate (2014-2019)
        • 3.5.2 Europe Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Glioblastoma Multiforme Therapeutics Production (2014-2019)
        • 3.6.1 China Glioblastoma Multiforme Therapeutics Production Growth Rate (2014-2019)
        • 3.6.2 China Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Glioblastoma Multiforme Therapeutics Production (2014-2019)
        • 3.7.1 Japan Glioblastoma Multiforme Therapeutics Production Growth Rate (2014-2019)
        • 3.7.2 Japan Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Glioblastoma Multiforme Therapeutics Consumption by Regions

      • 4.1 Global Glioblastoma Multiforme Therapeutics Consumption by Regions
      • 4.2 North America Glioblastoma Multiforme Therapeutics Consumption (2014-2019)
      • 4.3 Europe Glioblastoma Multiforme Therapeutics Consumption (2014-2019)
      • 4.4 China Glioblastoma Multiforme Therapeutics Consumption (2014-2019)
      • 4.5 Japan Glioblastoma Multiforme Therapeutics Consumption (2014-2019)

      5 Global Glioblastoma Multiforme Therapeutics Production, Revenue, Price Trend by Type

      • 5.1 Global Glioblastoma Multiforme Therapeutics Production Market Share by Type (2014-2019)
      • 5.2 Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Type (2014-2019)
      • 5.3 Global Glioblastoma Multiforme Therapeutics Price by Type (2014-2019)
      • 5.4 Global Glioblastoma Multiforme Therapeutics Production Growth by Type (2014-2019)

      6 Global Glioblastoma Multiforme Therapeutics Market Analysis by Applications

      • 6.1 Global Glioblastoma Multiforme Therapeutics Consumption Market Share by Application (2014-2019)
      • 6.2 Global Glioblastoma Multiforme Therapeutics Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Glioblastoma Multiforme Therapeutics Business

      • 7.1 Arbor Pharmaceuticals
        • 7.1.1 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Production Sites and Area Served
        • 7.1.2 Glioblastoma Multiforme Therapeutics Product Introduction, Application and Specification
        • 7.1.3 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Bristol-Myers Squibb
        • 7.2.1 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Production Sites and Area Served
        • 7.2.2 Glioblastoma Multiforme Therapeutics Product Introduction, Application and Specification
        • 7.2.3 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Eisai
        • 7.3.1 Eisai Glioblastoma Multiforme Therapeutics Production Sites and Area Served
        • 7.3.2 Glioblastoma Multiforme Therapeutics Product Introduction, Application and Specification
        • 7.3.3 Eisai Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 F. Hoffmann-La Roche
        • 7.4.1 F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Production Sites and Area Served
        • 7.4.2 Glioblastoma Multiforme Therapeutics Product Introduction, Application and Specification
        • 7.4.3 F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Merck
        • 7.5.1 Merck Glioblastoma Multiforme Therapeutics Production Sites and Area Served
        • 7.5.2 Glioblastoma Multiforme Therapeutics Product Introduction, Application and Specification
        • 7.5.3 Merck Glioblastoma Multiforme Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served

      8 Glioblastoma Multiforme Therapeutics Manufacturing Cost Analysis

      • 8.1 Glioblastoma Multiforme Therapeutics Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Glioblastoma Multiforme Therapeutics
      • 8.4 Glioblastoma Multiforme Therapeutics Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Glioblastoma Multiforme Therapeutics Distributors List
      • 9.3 Glioblastoma Multiforme Therapeutics Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Glioblastoma Multiforme Therapeutics Market Forecast

      • 11.1 Global Glioblastoma Multiforme Therapeutics Production, Revenue Forecast
        • 11.1.1 Global Glioblastoma Multiforme Therapeutics Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Glioblastoma Multiforme Therapeutics Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Glioblastoma Multiforme Therapeutics Price and Trend Forecast (2019-2025)
      • 11.2 Global Glioblastoma Multiforme Therapeutics Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Glioblastoma Multiforme Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Glioblastoma Multiforme Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Glioblastoma Multiforme Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Glioblastoma Multiforme Therapeutics Production, Revenue Forecast (2019-2025)
      • 11.3 Global Glioblastoma Multiforme Therapeutics Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Glioblastoma Multiforme Therapeutics Consumption Forecast (2019-2025)
        • 11.3.2 Europe Glioblastoma Multiforme Therapeutics Consumption Forecast (2019-2025)
        • 11.3.3 China Glioblastoma Multiforme Therapeutics Consumption Forecast (2019-2025)
        • 11.3.4 Japan Glioblastoma Multiforme Therapeutics Consumption Forecast (2019-2025)
      • 11.4 Global Glioblastoma Multiforme Therapeutics Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Glioblastoma Multiforme Therapeutics Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor. 
        Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.

        The global Glioblastoma Multiforme Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Glioblastoma Multiforme Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Glioblastoma Multiforme Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Arbor Pharmaceuticals
        Bristol-Myers Squibb
        Eisai
        F. Hoffmann-La Roche
        Merck
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Temozolomide
        Bevacozumab
        Carmustine

        Segment by Application
        Hospitals
        Clinics
        Others

        Buy now